

Financial news for ACRX dated on 2020-06-10: The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

Financial news for ACRX dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for ACRX dated on 2020-06-03: Acelrx Pharmaceuticals Will Be Paid a Break-up Fee of ~\$1.8M

Financial news for ACRX dated on 2020-06-03: AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetrphase

Financial news for ACRX dated on 2020-06-02: The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To \$500M In Biotech

Financial news for ACRX dated on 2020-06-02: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACRX dated on 2020-06-01: UPDATE: Under Amended Melinta Proposal, Melinta Has Offered To Acquire Tetrphase For \$39M In Cash Plus \$16M In Cash Potentially Payable Under Contingent Value Rights

Financial news for ACRX dated on 2020-05-29: UPDATE: Tetrphase Announces \$37M Valuation, \$18.7M In Stock Warrants, In Merger With AcelRx

Financial news for ACRX dated on 2020-05-29: AcelRx Pharmaceuticals Announces Revised Merger Agreement With Tetrphase

Financial news for ACRX dated on 2020-05-28: The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetrphase Receives Sweetened Offer

Financial news for ACRX dated on 2020-05-27: Tetrphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

Financial news for ACRX dated on 2020-05-27: UPDATE: Tetrphase Shareholders Will Receive For Each Share \$0.2434/Share In Cash, 0.7217 Shares Of AcelRx Common Stock, 1 Contingent Value Right

Financial news for ACRX dated on 2020-05-27: AcelRx Reports Revised Consideration For Tetrphase Deal: \$30M In Stock And Cash Plus Added \$14.5M In Contingent Value Rights Payable In Cash

Financial news for ACRX dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for ACRX dated on 2020-05-15: UPDATE: Tetrphase Board Determine Melinta Offer Could Reasonably Be Expected To Lead To A Superior Offer As Defined In AcelRx Deal

Financial news for ACRX dated on 2020-05-13: Tetrphase Says On May 12 Received Revised Proposal From La Jolla Pharmaceutical For \$22.3M In Cash Plus Additional \$12.5M In Cash Under Contingent Value; Co.'s Board At This Time Continues To Recommend AcelRx Merger Agreement

Financial news for ACRX dated on 2020-05-11: AcelRx Pharmaceuticals Q1 EPS \$(0.200) Misses \$(0.170) Estimate, Sales \$386.000K Up From \$265.000K YoY

Financial news for ACRX dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for ACRX dated on 2020-05-07: Bidding War Sends Tetrphase Shares Soaring

Financial news for ACRX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for ACRX dated on 2020-04-30: AcelRx shares are trading higher after the company announced DSUVIA has received Milestone C approval.

Financial news for ACRX dated on 2020-04-30: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2020-04-30: AcelRx Announces DSUVIA(r) Milestone C Approval

Financial news for ACRX dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for ACRX dated on 2020-03-17: H.C. Wainwright Maintains Buy on AcetRx Pharmaceuticals, Lowers Price Target to \$7

Financial news for ACRX dated on 2020-03-16: AcetRx Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 sales results.

Financial news for ACRX dated on 2020-03-16: AcetRx Pharmaceuticals: Q4 Earnings Insights

Financial news for ACRX dated on 2020-03-16: AcetRx Pharmaceuticals Q4 EPS \$(0.18) Beats \$(0.2) Estimate, Sales \$475K Miss \$1.01M Estimate

Financial news for ACRX dated on 2020-03-16: AcetRx Pharmaceuticals To Acquire Tetrphase Pharmaceuticals For 0.6303 AcetRx Shares For Each Share Of Tetrphase

Financial news for ACRX dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for ACRX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for ACRX dated on 2020-03-10: AcetRx Announces Confirmed Timing Of Department Of Defense Milestone C Meeting For April

Financial news for ACRX dated on 2020-03-06: AcetRx Announces Agreement For Investigator-Initiated Study Of DSUVIA In Patients Undergoing Spine Surgery

Financial news for ACRX dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for ACRX dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for ACRX dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ACRX dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for ACRX dated on 2020-02-25: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ACRX dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for ACRX dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for ACRX dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for ACRX dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for ACRX dated on 2020-02-18: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ACRX dated on 2020-01-13: AcetRx Sees Prelim. FY19 Sales \$2.3M, Cash, Cash Equivalents And Short-Term Investments Of \$66.1M As Of Dec. 31

Financial news for ACRX dated on 2019-12-12: 70 Biggest Movers From Yesterday

Financial news for ACRX dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for ACRX dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ACRX dated on 2019-11-13: AcetRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

Financial news for ACRX dated on 2019-11-12: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ACRX dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for ACRX dated on 2019-11-11: Stocks That Hit 52-Week Lows On Monday

Financial news for ACRX dated on 2019-11-11: Benzinga's Top Upgrades, Downgrades For November 11, 2019

Financial news for ACRX dated on 2019-11-11: 10 Biggest Price Target Changes For Monday

Financial news for ACRX dated on 2019-11-11: Credit Suisse Downgrades AcelRx Pharmaceuticals to Neutral, Lowers Price Target to \$2

Financial news for ACRX dated on 2019-11-07: Stocks That Hit 52-Week Lows On Thursday

Financial news for ACRX dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for ACRX dated on 2019-11-06: AcelRx Pharmaceuticals Q3 EPS \$(0.16) Beats \$(0.22) Estimate, Sales \$608K Miss \$960K Estimate

Financial news for ACRX dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for ACRX dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for ACRX dated on 2019-08-05: AcelRx Pharmaceuticals Q2 EPS \$(0.16) Beats \$(0.22) Estimate, Sales \$941K Miss \$1.1M Estimate

Financial news for ACRX dated on 2019-08-05: Credit Suisse Assumes AcelRx Pharmaceuticals at Outperform, Announces \$7 Price Target

Financial news for ACRX dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for ACRX dated on 2019-07-29: 62 Biggest Movers From Friday

Financial news for ACRX dated on 2019-07-11: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2019-07-10: Credit Suisse Assumes AcelRx Pharmaceuticals at Outperform

Financial news for ACRX dated on 2019-07-01: 60 Biggest Movers From Friday

Financial news for ACRX dated on 2019-06-28: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2019-05-30: 64 Biggest Movers From Yesterday

Financial news for ACRX dated on 2019-05-08: AcelRx Pharmaceuticals Q1 EPS \$(0.17) Beats \$(0.22) Estimate, Sales \$265K Miss \$750K Estimate

Financial news for ACRX dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for ACRX dated on 2019-05-06: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2019-04-24: B. Riley FBR Initiates Coverage On AcelRx Pharmaceuticals, Inc. - Common Stock with Buy Rating

Financial news for ACRX dated on 2019-04-11: Acelrx Pharmaceutical's Pooled Safety Results For Sufentanil Sublingual Tablets Selected For Presentation At 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting Redwood City, Calif., April 11, 2019

Financial news for ACRX dated on 2019-03-11: AcelRx Pharmaceuticals To Present At Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

Financial news for ACRX dated on 2019-03-11: 70 Biggest Movers From Friday

Financial news for ACRX dated on 2019-03-08: AcelRx Pharmaceuticals shares are trading lower after the company reported less-than-expected Q4 sales results.

Financial news for ACRX dated on 2019-03-08: The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings

Financial news for ACRX dated on 2019-03-07: AcelRx Pharmaceuticals Q4 EPS \$(0.18) Beats \$(0.20) Estimate, Sales \$613K Miss \$1.51M Estimate

Financial news for ACRX dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for ACRX dated on 2019-03-04: 81 Biggest Movers From Friday

Financial news for ACRX dated on 2019-03-03: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for ACRX dated on 2019-03-01: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2019-02-20: 71 Biggest Movers From Yesterday

Financial news for ACRX dated on 2019-02-19: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACRX dated on 2019-02-19: 61 Biggest Movers From Friday

Financial news for ACRX dated on 2019-02-15: 52 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2019-02-15: Benzinga's Top Upgrades, Downgrades For February 15, 2019

Financial news for ACRX dated on 2019-02-15: Credit Suisse Initiates Coverage On AcelRx Pharmaceuticals with Outperform Rating, Announces \$7 Price Target

Financial news for ACRX dated on 2019-02-15: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2019-01-31: AcelRx Pharma Reports DSUVIA Will Be Highlighted During Presentation At Boswick Burn, Wound Symposium

Financial news for ACRX dated on 2019-01-18: 40 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2018-12-24: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-12-18: AcelRx Pharmaceuticals Added To NASDAQ Biotechnology Index

Financial news for ACRX dated on 2018-12-10: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-11-26: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-11-21: 50 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-11-20: Shares of AcelRx Pharmaceuticals are trading up 10.3% after the Chief Medical Officer bought 16k shares at \$3.07/share.

Financial news for ACRX dated on 2018-11-20: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACRX dated on 2018-11-13: Acelrx Pharmaceuticals CFO Asadorian Buys 5,000 @ Avg Price: \$3.13

Financial news for ACRX dated on 2018-11-12: 85 Biggest Movers From Friday

Financial news for ACRX dated on 2018-11-09: 68 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2018-11-09: AcelRx Prices ~12.7M Share Common Stock Offering At \$3.15/Share

Financial news for ACRX dated on 2018-11-09: Hearing AcelRx Pharma Offering Priced At \$3.15/Share

Financial news for ACRX dated on 2018-11-09: 34 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2018-11-09: AcelRx Reports Offering Of Common Shares, No Terms Disclosed

Financial news for ACRX dated on 2018-11-05: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Mon., Nov. 5, 2018

Financial news for ACRX dated on 2018-11-05: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for ACRX dated on 2018-11-02: AcelRx Pharmaceuticals Q3 EPS \$(0.21) Up From \$(0.28) YoY, Sales \$377K Down From \$1.487M YoY

Financial news for ACRX dated on 2018-11-02: Ladenburg Thalmann Reiterates Buy And \$100 Price Target On AcelRx Following FDA Approval Of DSUVIA; Firm Says Approval Supports Firm's Expectations, Not Making Any Changes To Revenue Estimates

Financial news for ACRX dated on 2018-11-02: AcelRx shares are trading up 7% after the FDA approved the company's DSUVIA pain medication.

Financial news for ACRX dated on 2018-11-02: AcelRx Shares Resume Trade

Financial news for ACRX dated on 2018-11-02: AcelRx Shares To Resume Trade At 2:15 p.m. ET

Financial news for ACRX dated on 2018-11-02: AcelRx Press Release Confirms FDA Approval For DSUVIA

Financial news for ACRX dated on 2018-11-02: AcelRx Says Sees US Launch Of DSUVIA In Q1'19

Financial news for ACRX dated on 2018-11-02: UPDATE: FDA Commissioner Scott Gottlieb Says There Are 'Very Tight Restrictions' Being Placed On Distribution And Use Of Dsuvia, Says FDA Will Continue To Monitor Implementation Or Risk Evaluation And Mitigation Strategy Associated With Drug

Financial news for ACRX dated on 2018-11-02: FDA Has Approved AcelRx's Pain Medication, Dsuvia

Financial news for ACRX dated on 2018-11-02: AcelRx Shares Halted News Pending

Financial news for ACRX dated on 2018-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for ACRX dated on 2018-10-29: Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?

Financial news for ACRX dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ACRX dated on 2018-10-26: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2018-10-25: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2018-10-24: 56 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-23: B. Riley FBR Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces \$9 Price Target

Financial news for ACRX dated on 2018-10-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-10-22: 58 Biggest Movers From Friday

Financial news for ACRX dated on 2018-10-17: Aclaris Therapeutics shares are down 6.0% after the company reported a common stock offering.

Financial news for ACRX dated on 2018-10-17: 48 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-16: 10 Hottest Stocks From October 16, 2018

Financial news for ACRX dated on 2018-10-16: Benzinga Pro's Top 10 Most-Searches Tickers For Afternoon Of Tues., Oct. 16, 2018

Financial news for ACRX dated on 2018-10-16: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACRX dated on 2018-10-16: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACRX dated on 2018-10-16: 42 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-15: 10 Hottest Stocks From October 15, 2018

Financial news for ACRX dated on 2018-10-15: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Mon., Oct. 15, 2018

Financial news for ACRX dated on 2018-10-15: AcelRx Pharmaceuticals Option Alert: Nov 16 \$5 Calls Sweep (5) near the Bid: 502 @ \$0.551 vs 4657 OI; Earnings 11/8 After Close [est] Ref=\$4.235

Financial news for ACRX dated on 2018-10-15: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for ACRX dated on 2018-10-15: AcelRx Pharmaceuticals Option Alert: Dec 21 \$5 Calls at the Bid: 4213 @ \$0.7 vs 8706 OI; Earnings 11/8 After Close [est] Ref=\$4.3469

Financial news for ACRX dated on 2018-10-15: Mid-Day Market Update: Cambium Learning Surges On Acquisition News; CPI Aerostructures Shares Drop

Financial news for ACRX dated on 2018-10-15: Mid-Morning Market Update: Markets Open Lower; Bank of America Earnings Beat Expectations

Financial news for ACRX dated on 2018-10-15: Benzinga's Top Upgrades, Downgrades For October 15, 2018

Financial news for ACRX dated on 2018-10-15: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-10-15: Jefferies Upgrades AcelRx Pharmaceuticals to Buy, Announces \$8 Price Target

Financial news for ACRX dated on 2018-10-15: A Peek Into The Markets: US Stock Futures Down Ahead Of Retail Sales Data

Financial news for ACRX dated on 2018-10-15: 44 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-15: 5 Stocks To Watch For October 15, 2018

Financial news for ACRX dated on 2018-10-12: AcelRX Pharma Shares Resume Trade, Up 10.7%

Financial news for ACRX dated on 2018-10-12: AcelRX Pharma Shares To Resume Trade at 4:45pm ET

Financial news for ACRX dated on 2018-10-12: AcelRX Pharma FDA AdCom Votes 10-3 In Favor Approval of DSUVIA

Financial news for ACRX dated on 2018-10-12: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2018-10-12: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for ACRX dated on 2018-10-12: AcelRx Pharma Shares Halted Ahead Of FDA AdCom Panel For DSUVIA

Financial news for ACRX dated on 2018-10-12: AcelRx Pharma Shares Halted News Pending

Financial news for ACRX dated on 2018-10-12: 44 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-11: 41 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-10: 10 Hottest Stocks From October 10, 2018

Financial news for ACRX dated on 2018-10-10: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Wed., Oct. 10, 2018

Financial news for ACRX dated on 2018-10-10: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACRX dated on 2018-10-10: AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia

Financial news for ACRX dated on 2018-10-10: AcelRx Pharmaceuticals are up 26%; Shares dipped in the pre-market session amid reports of negative FDA comments on the company's Dsuvia, although analysts at Ladenburg Thalmann reiterated a Buy rating and

raised the stock's price target to \$10.

Financial news for ACRX dated on 2018-10-10: Ladenburg Thalmann Reiterates Buy on AcelRx Pharmaceuticals, Raises Price Target to \$10

Financial news for ACRX dated on 2018-10-10: AcelRx Pharma Shares Fall 50.9%; Hearing FDA Staff Has Highlighted Co.'s Dsuvia Offers 'No Apparent Advantage Over Currently Available Therapies,' FDA Staff Highlights Risks Of Misplaced Tablets Of Dsuvia

Financial news for ACRX dated on 2018-10-10: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACRX dated on 2018-10-10: 46 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for ACRX dated on 2018-10-03: 45 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for ACRX dated on 2018-09-25: 51 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-09-11: AcelRx Announces October 12 Date Of FDA Advisory Committee Meeting For DSUVIA

Financial news for ACRX dated on 2018-08-16: AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation

Financial news for ACRX dated on 2018-08-16: Benzinga's Top Upgrades, Downgrades For August 16, 2018

Financial news for ACRX dated on 2018-08-16: Ladenburg Thalmann Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces \$7 Price Target

Financial news for ACRX dated on 2018-08-06: 66 Biggest Movers From Friday

Financial news for ACRX dated on 2018-08-03: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2018-08-02: AcelRx Pharmaceuticals Q2 EPS \$(0.20), Inline, Sales \$818K Miss \$910K Estimate

Financial news for ACRX dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for ACRX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for ACRX dated on 2018-07-23: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-07-13: Oppenheimer Initiates Coverage On AcelRx Pharmaceuticals with Perform Rating

Financial news for ACRX dated on 2018-07-13: 44 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-07-12: 30 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACRX dated on 2018-07-12: Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Earnings Beat Estimates

Financial news for ACRX dated on 2018-07-12: AcelRx Pharma Prices ~7.27M Share Common Stock Offering At \$2.75/Share

Financial news for ACRX dated on 2018-07-12: Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

Financial news for ACRX dated on 2018-07-12: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2018-07-12: 7 Stocks To Watch For July 12, 2018

Financial news for ACRX dated on 2018-07-11: 6 Stocks Moving In Wednesday's After-Hours Session

Financial news for ACRX dated on 2018-07-11: AcelRx Pharma 8-K Shows Expectation For

~\$50M In Cash, Cash Equivalents, Short-Term Investments As Of Jun. 30, 2018

Financial news for ACRX dated on 2018-07-11: AcetRx Pharmaceuticals Announces Commencement Of Common Stock Offering; No Size Disclosed

Financial news for ACRX dated on 2018-06-27: 23 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACRX dated on 2018-06-27: AcetRx Receives European Commission Approval for DZUVEO

Financial news for ACRX dated on 2018-06-12: Analyst: AcetRx Will Address FDA Concerns, Secure Approval This Year

Financial news for ACRX dated on 2018-06-12: Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

Financial news for ACRX dated on 2018-06-11: Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating

Financial news for ACRX dated on 2018-05-31: Leerink Revelation Healthcare Fund Reports 7.3% Stake In AcetRx

Financial news for ACRX dated on 2018-05-25: 45 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-05-24: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACRX dated on 2018-05-24: AcetRx Earlier Announced That FDA Accepted Resubmission Of NDA For Co.'s DSUVIA Pain Management Therapy; Shares Up 11.1% Premarket

Financial news for ACRX dated on 2018-05-24: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2018-05-23: AcetRx Pharma Reports All Of Co. Shares Owned By Three Arch Partners Were Purchased By Investors Led By Leerink revelation Partners; Included ~9.37M Shares Across All Funds; Co. Did Not Receive Proceeds From Sale

Financial news for ACRX dated on 2018-05-21: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2018-05-15: AcetRx Pharmaceuticals Shares Up 10.8% On Heavy Volume, No Apparent News

Financial news for ACRX dated on 2018-05-09: AcetRx Pharmaceuticals Q1 EPS \$(0.23) Beats \$(0.24) Estimate, Sales \$343K Miss \$1.15M Estimate

Financial news for ACRX dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for ACRX dated on 2018-05-09: AcetRx resubmits New Drug Application for DSUVIA

Financial news for ACRX dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for ACRX dated on 2018-04-30: AcetRx Pharma Announces the Publication of a Study Funded by the Company

Financial news for ACRX dated on 2018-04-27: AcetRx Pharma Shares Up 13% Premarket; Co. Earlier Announced Positive CHMP Opinion For DZUVEO For Mgmt. Of Acute Moderate To Severe Pain In Medically Monitored Settings

Financial news for ACRX dated on 2018-04-18: AcetRx Pharma Announces Publication that Sublingual Sufentanil Tablets Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting

Financial news for ACRX dated on 2018-04-16: 11 Stocks Moving In Monday's After-Hours Session

Financial news for ACRX dated on 2018-04-16: AcetRx Confirms Plans to Resubmit NDA in Q2 2018

Financial news for ACRX dated on 2018-03-27: 41 Biggest Movers From Yesterday

Financial news for ACRX dated on 2018-03-12: 44 Biggest Movers From Friday

Financial news for ACRX dated on 2018-03-09: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for ACRX dated on 2018-03-09: AcelRX Shares Up 10.3% After Co. Announced Planned Resubmission Of NDA For DSUVIA In Q2

Financial news for ACRX dated on 2018-03-09: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2018-03-08: AcelRX Shares Up 7.6% After Hours As Co. Plans Resubmission Of NDA For DSUVIA In Q2

Financial news for ACRX dated on 2018-03-08: AcelRx Pharmaceuticals Reports Q4 EPS \$(0.20) vs \$(0.20) Est., Sales \$740K

Financial news for ACRX dated on 2017-11-16: AcelRx Highlights Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain, Showed '30 mcg tablet was effective and well-tolerated for the management of moderate-to-severe acute pain...'

Financial news for ACRX dated on 2017-11-09: AcelRx Pharmaceuticals Reports Q3 EPS \$(0.28) vs \$(0.27) Est., Sales \$1.48M vs \$2.22M Est.

Financial news for ACRX dated on 2017-10-23: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2017-10-23: AcelRx +10% Premarket @\$2.20; Co Announced Friday DSUVIA Clinical Trial Results Selected as a Top Abstract for Oral Presentation at ASA's Annual Meeting

Financial news for ACRX dated on 2017-10-20: AcelRx Reports DSUVIA Trial Results Selected As Top Abstract for Oral Presentation At ASA Annual Meeting

Financial news for ACRX dated on 2017-10-13: Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback

Financial news for ACRX dated on 2017-10-13: Benzinga's Top Upgrades, Downgrades For October 13, 2017

Financial news for ACRX dated on 2017-10-13: The Market In 5 Minutes: Trump To End Key ACA Subsidies, McGowan Speaks Out, Amazon Studio Exec Suspended

Financial news for ACRX dated on 2017-10-13: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for ACRX dated on 2017-10-13: Jefferies Downgrades AcelRx Pharmaceuticals to Hold

Financial news for ACRX dated on 2017-10-12: Mid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher

Financial news for ACRX dated on 2017-10-12: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACRX dated on 2017-10-12: Mid-Day Market Update: J.Jill Tumbles Following Weak Q3 Outlook; Ardelyx Shares Surge

Financial news for ACRX dated on 2017-10-12: Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates

Financial news for ACRX dated on 2017-10-12: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2017-10-12: AcelRx Pharma Gets a Complete Response Letter from the FDA

Financial news for ACRX dated on 2017-10-11: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACRX dated on 2017-10-10: AcelRX Pharma Shares Up 5.29% On Heavy Volume Ahead Of Thursday PDUFA Date For DSUVIA

Financial news for ACRX dated on 2017-10-09: The Week Ahead: New IPOs, Bank Earnings, And Some Notable FDA Actions

Financial news for ACRX dated on 2017-10-05: Watching Flexion, AxelRx, Agile Therapeutics Shares Premarket Thurs. Following Reuters Highlighting 'RBC sees 3 small-cap drugmakers as candidates for takeover'; Stocks Not Moving

Financial news for ACRX dated on 2017-10-02: Early FDA Approval Speculation Sends AcelRX Pharma Shares Soaring

Financial news for ACRX dated on 2017-10-02: 20 Biggest Mid-Day Gainers For Monday

Financial news for ACRX dated on 2017-10-02: Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss

Financial news for ACRX dated on 2017-10-02: AcelRx Shares Up 5.5% Premarket; Biotech Investor And Head Of IP For DSM Sinochem Pharma, James DeYonker On Twitter Speculates About Possible Early PDUFA Approval

Financial news for ACRX dated on 2017-10-02: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2017-09-28: FDA Says It Sent Letters To 74 Manufacturers Of Opioid Analgesics Intended For Outpatient Use, Will Soon Issue Guidance For Applicants Seeking Approval For Generic Versions Of Abuse-Deterrent Opioids

Financial news for ACRX dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for ACRX dated on 2017-09-26: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for ACRX dated on 2017-08-30: Born On The Battlefield: AcelRx Awaits FDA Ruling On Device That Delivers Potent Opioid To Wounded Soldiers

Financial news for ACRX dated on 2017-08-29: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for ACRX dated on 2017-08-23: 13G/A Filing From Perceptive Advisors Shows 2.7% Stake In AcelRX Pharmaceuticals

Financial news for ACRX dated on 2017-08-09: AcelRx Shares Pop to High of \$3.10; Traders Circulate Agora Note With \$9 PT

Financial news for ACRX dated on 2017-08-02: 18 Biggest Mid-Day Losers For Wednesday

Financial news for ACRX dated on 2017-08-01: Mid-Afternoon Market Update: Crude Oil Down 2.5%; Horizon Global Shares Spike Higher

Financial news for ACRX dated on 2017-08-01: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ACRX dated on 2017-08-01: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACRX dated on 2017-08-01: AcelRx Pharmaceuticals Reports Q2 EPS \$(0.29) vs \$(0.28) Est., Sales \$2.65M vs \$2.27M Est.

Financial news for ACRX dated on 2017-08-01: AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality, AcelRx Remains on Track to Resubmit NDA by End of 2017

Financial news for ACRX dated on 2017-07-24: 18 Biggest Mid-Day Gainers For Monday

Financial news for ACRX dated on 2017-07-20: Mid-Morning Market Update: Markets Mostly Flat; Philip Morris Profit Misses Estimates

Financial news for ACRX dated on 2017-07-19: AcelRx Pharmaceuticals Names Raffi Asadorian CFO

Financial news for ACRX dated on 2017-07-17: 18 Biggest Mid-Day Gainers For Monday

Financial news for ACRX dated on 2017-07-17: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2017-06-05: S-3 from AcelRx Pharma Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for ACRX dated on 2017-06-05: AcelRX CFO Resigns

Financial news for ACRX dated on 2017-05-08: AcelRx Pharma Reports Q1 EPS \$(0.34) vs \$(0.27) Est., Sales \$3.109M vs \$1.8M Est.

Financial news for ACRX dated on 2017-04-18: Mid-Day Market Update: Dow Drops Over 100 Points; Arena Pharmaceuticals Shares Plummet

Financial news for ACRX dated on 2017-04-17: SIRF Report's Roddy Boyd Tweets: This

DSuvia thing = a real test of FDA resolve as there's no apparent medical need for it
@acelrx_pharma

Financial news for ACRX dated on 2017-04-17: SIRF Reporter Roddy Boyd Tweets: The next chap in unexpected prescription deaths I'll be covering: @acelrx_pharma Dsuvia sublingual tablets, ~10x stronger than Fentanyl

Financial news for ACRX dated on 2017-04-16: What Success Is Made Of: Investors, Execs And Entrepreneurs Talk About Their Routines And Role Models - Part 2

Financial news for ACRX dated on 2017-04-10: What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models

Financial news for ACRX dated on 2017-04-06: AcelRx Reports Comprehensive DSUVIA Trial Results: Says 480 Patients Enrolled Across 4 Late-Phase Studies

Financial news for ACRX dated on 2017-03-28: AcelRx Pharmaceuticals Announces The EMA Has Notified Company That ARX-04 MAA Passed Validation And Scientific Review Is Underway

Financial news for ACRX dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for ACRX dated on 2017-03-08: Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gutermann

Financial news for ACRX dated on 2017-03-03: Family Office Legend Thomas Gutermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns'

Financial news for ACRX dated on 2017-03-02: AcelRx Pharmaceuticals Reports Q4 EPS \$(0.21) vs. \$(0.24) Est., Sales \$6.4M

Financial news for ACRX dated on 2017-02-28: AcelRx CFO Shares Update On DoD Relationship And More After FDA Accepted NDA For DSUVIA

Financial news for ACRX dated on 2017-02-27: 15 Biggest Mid-Day Gainers For Monday

Financial news for ACRX dated on 2017-02-27: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2017-02-27: AcelRx Pharmaceuticals Shares Up 6.6% Premarket As Co. Announced NDA For Dsuvia Accepted For Filing With PDUFA Date Of Oct. 12th

Financial news for ACRX dated on 2017-02-16: AcelRx Pharma Names Vincent Angotti CEO

Financial news for ACRX dated on 2017-02-16: Exclusive: AcelRx Pharma Execs Discuss Stock Performance, Catalysts And Financial Position

Financial news for ACRX dated on 2017-02-15: AcelRx: Replacing Morphine With Department Of Defense Funding

Financial news for ACRX dated on 2017-01-12: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2017-01-08: AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for DSUVIA for the Treatment of Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2017-01-08: AcelRx Pharmaceuticals Announces DSUVIA as Brand Name for ARX-04 in the US

Financial news for ACRX dated on 2016-12-13: AcelRx Pharma Submits NDA for ARX-04

Financial news for ACRX dated on 2016-11-16: Jefferies London Healthcare Conference Taking Place Today

Financial news for ACRX dated on 2016-11-01: AcelRx Pharmaceuticals Reports Q3 EPS \$(0.25) vs. Est. \$(0.23), Rev. \$3.36M vs. Est. \$2.89M

Financial news for ACRX dated on 2016-09-28: AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine

Financial news for ACRX dated on 2016-09-27: AcelRx Begins Phase 3 Study of Zalviso in Patients with Moderate-to-Severe Acute Post-Operative Pain

Financial news for ACRX dated on 2016-09-15: Mid-Afternoon Market Update: Dow Up Over 200 Points; Lakeland Industries Shares Spike Higher

Financial news for ACRX dated on 2016-09-15: Mid-Afternoon Market Update: Dow Up Over 200 Points; Lakeland Industries Shares Spike Higher

Financial news for ACRX dated on 2016-09-15: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ACRX dated on 2016-09-15: Mid-Day Market Update: NASDAQ Rises Over 1%; AcetRx Shares Surge After Positive Results From Its Trial On ARX-04

Financial news for ACRX dated on 2016-09-15: Mid-Morning Market Update: Markets Rise; Aerie Pharmaceuticals Reports Positive Roclatan Phase 3 Topline Efficacy Results

Financial news for ACRX dated on 2016-09-15: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACRX dated on 2016-09-15: A Peek Into The Markets: U.S. Stock Futures Climb Ahead Of Economic Data

Financial news for ACRX dated on 2016-09-15: AcetRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04

Financial news for ACRX dated on 2016-09-15: AcetRx Reports Positive Results for ARX-04, Says Intends to Submit NDA

Financial news for ACRX dated on 2016-09-14: AcetRx Pharma Will Report Topline Results from Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain on Sept. 15, 2016

Financial news for ACRX dated on 2016-08-15: 12 Stocks Moving In Monday's Pre-Market Session

Financial news for ACRX dated on 2016-08-15: AcetRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint

Financial news for ACRX dated on 2016-08-15: AcetRx +19% Premarket at \$4.44 as Phase 3 Trial of ARX-04 Met Primary Endpoint

Financial news for ACRX dated on 2016-08-15: AcetRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2016-07-28: AcetRx Pharma Reports Q2 EPS \$(0.24) vs \$(0.22) Est., Sales \$4.531M vs \$2.17M Est.

Financial news for ACRX dated on 2016-07-08: AcetRx Pharmaceuticals Says Start Date for IAP312 Study was Revised to September 2016 -8K

Financial news for ACRX dated on 2016-06-28: AcetRx Says Had \$106M in Cash on Hand as of End of Q1

Financial news for ACRX dated on 2016-06-28: AcetRx Reports Completion of Patient Enrollment in Remaining Phase 3 Studies of ARX-04 for Treatment of Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2016-06-21: Filing from AcetRx Shows Registration for \$40M Common Stock Offering

Financial news for ACRX dated on 2016-05-26: AcetRx Pharmaceuticals SAP301 Study Met Primary Endpoint In Pain Intensity Differences

Financial news for ACRX dated on 2016-05-06: Seaport Global Upgrades AcetRx Pharmaceuticals to Buy

Financial news for ACRX dated on 2016-05-06: AcetRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX-04 by Type of Abdominal Surgery

Financial news for ACRX dated on 2016-05-02: AcetRx Reports Q1 EPS \$(0.25) vs \$(0.20) Est., Sales \$3.025M vs \$1.62M Est.

Financial news for ACRX dated on 2016-03-29: UPDATE: AcetRX Pharma Says 'We have successfully transitioned ARX-04 into late-stage development, defined the regulatory pathway for ARX-04 and Zalviso in the U.S.'

Financial news for ACRX dated on 2016-03-29: AcetRx Pharmaceuticals Names Howard B. Rosen as CEO, Provides Update on Clinical Development Activities

Financial news for ACRX dated on 2016-03-07: AcetRX Pharma Reports Q4 EPS \$(0.24) Vs Est \$(0.10), Expects To Submit NDA For ARX-04 In Q4

Financial news for ACRX dated on 2016-03-07: AcetRex Pharma Reports Initiation of

Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2016-03-07: Earnings Scheduled For March 7, 2016

Financial news for ACRX dated on 2016-02-25: AcelRx Phase 3 Interim Analysis For Moderate-To-Severe Pain ARX-04 Shows Improved Pain Scores

Financial news for ACRX dated on 2016-02-11: AcelRx Pharma Reports Presentation of Phase 3 Results from ARX-04 Program at JAB Burn, Wound Care Symposium

Financial news for ACRX dated on 2016-01-26: Acelrx Spikes to High of \$3.33 on Volume

Financial news for ACRX dated on 2016-01-21: AcelRx Pharma. Reports Phase 3 Sublingual Data

Financial news for ACRX dated on 2016-01-10: AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones for Product Portfolio

Financial news for ACRX dated on 2016-01-08: AcelRx Closes Protocol Review with FDA, Says Plans to Commence Phase 3 Open-Label Study for Zalviso in Q1

Financial news for ACRX dated on 2015-12-23: AcelRx Pharmaceuticals Given Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency

Financial news for ACRX dated on 2015-12-22: Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide

Financial news for ACRX dated on 2015-12-14: AcelRx Pharma. Conducts Meeting With US FDA Pre-NDA

Financial news for ACRX dated on 2015-11-19: AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

Financial news for ACRX dated on 2015-11-04: AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

Financial news for ACRX dated on 2015-11-04: AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

Financial news for ACRX dated on 2015-10-29: AcelRx Reports Q3 EPS \$0.11 vs. Est. \$(0.23), Rev. \$15.428M vs. Est. \$1.75M; Estimates Not Comp.

Financial news for ACRX dated on 2015-10-09: AcelRX Pharmaceuticals Reports Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting

Financial news for ACRX dated on 2015-10-08: AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso

Financial news for ACRX dated on 2015-10-08: AcelRx Pharma Offers Regulatory Update on Zalviso: Minutes from FDA's DAAAP Meeting Showed Restated Request for Clinical Data to Complement Other Data AcelRx Developed

Financial news for ACRX dated on 2015-10-06: AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2015-09-22: AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients; Triggers \$15M Payment Milestone

Financial news for ACRX dated on 2015-09-21: Morning Market Gainers

Financial news for ACRX dated on 2015-09-21: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2015-09-21: PDL BioPharma Announces Acquisition of Portion of AcelRx Pharma, Royalties, Expected Milestones from Zalviso for \$65M

Financial news for ACRX dated on 2015-09-09: Morning Market Gainers

Financial news for ACRX dated on 2015-09-09: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2015-09-09: 8-K from AcelRx Pharma Shows ARX-04 Has Met All Endpoints in PIVOTAL Phase 3 Study for Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2015-09-08: Morning Market Losers

Financial news for ACRX dated on 2015-09-08: Benzinga's Top #PreMarket Losers

Financial news for ACRX dated on 2015-09-02: 3 Catalysts To Watch Over The Next Couple Months For This Pharma Co.

Financial news for ACRX dated on 2015-07-24: Morning Market Gainers

Financial news for ACRX dated on 2015-07-24: AcelRx Reports Positive CHMP Opinion for Zalviso for Acute Moderate to Sever Post-Operative Pain

Financial news for ACRX dated on 2015-07-24: AcelRx Pharmaceuticals Shares +15% Premarket; Hearing Positive EMA Recommendation for Sufentanil

Financial news for ACRX dated on 2015-07-23: Option Alert: AcelRx Pharma Aug \$5 Call; 1261 Contracts Traded vs 465 OI; Now \$4.45

Financial news for ACRX dated on 2015-07-02: Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain

Financial news for ACRX dated on 2015-05-19: 7 Biotech Stocks Moving Off The UBS Healthcare Conference

Financial news for ACRX dated on 2015-05-14: Morning Market Gainers

Financial news for ACRX dated on 2015-05-14: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2015-05-14: US Stock Futures Surge Ahead Of Jobless Claims

Financial news for ACRX dated on 2015-05-14: AcelRx Awarded Up to \$17M Contract from Department of Defense to Advance ARX-04

Financial news for ACRX dated on 2015-05-05: Stocks Hitting 52-Week Lows

Financial news for ACRX dated on 2015-05-05: Morning Market Losers

Financial news for ACRX dated on 2015-05-05: Benzinga's Top #PreMarket Losers

Financial news for ACRX dated on 2015-05-04: Bill Ackman Boosts Jarden; Nautilus Wins Big In After-Hours Trading

Financial news for ACRX dated on 2015-05-04: AcelRx Shares to Resume Trade at 4:30 p.m. EDT

Financial news for ACRX dated on 2015-05-04: AcelRx Reports Q1 GAAP Loss of \$0.27/Share, May Not Compare to \$0.44/Share Gain Est.; Co. Says FDA Panel Restated View Clinical Study is Necessary, Request for Meeting was Denied

Financial news for ACRX dated on 2015-05-04: AcelRx Shares Halted News Pending

Financial news for ACRX dated on 2015-04-27: Global Hunter Initiates Coverage on AcelRx Pharmaceuticals at Accumulate, Announces \$22.00 PT

Financial news for ACRX dated on 2015-03-30: Stocks Hitting 52-Week Lows

Financial news for ACRX dated on 2015-03-23: 8-K from AcelRx Pharma Shows Grunenthal Confirmed CHMP of EMA Received Responses, Says Expecting to Get EMA Day-180 List of Issues During Q2

Financial news for ACRX dated on 2015-03-20: 9 Management Changes From The Past Week

Financial news for ACRX dated on 2015-03-20: AcelRx Reports Restructure To Focus On Zalviso Approval; Cutting 19 Jobs, Will Incur \$900K Chare For Cuts

Financial news for ACRX dated on 2015-03-20: AcelRx Names Howard Rosen Interim CEO

Financial news for ACRX dated on 2015-03-16: AcelRx Pharma Reports Initiation of Pivotal Phase 3 Trial for ARX-04 for Treatment of Moderate-to-Severe Acute Pain

Financial news for ACRX dated on 2015-03-10: Jefferies Downgrades AcelRx Pharmaceuticals After FDA Requests Additional Clinical Trial For Lead Drug Zalviso

Financial news for ACRX dated on 2015-03-10: Cowen & Company Downgrades AcelRx Pharmaceuticals to Market Perform, Removes \$14.00 PT

Financial news for ACRX dated on 2015-03-10: Jefferies Downgrades AcelRx Pharmaceuticals To Hold

Financial news for ACRX dated on 2015-03-10: Benzinga's Top Downgrades

Financial news for ACRX dated on 2015-03-10: Jefferies Downgrades AcelRx Pharmaceuticals to Hold, Lowers PT to \$6.00

Financial news for ACRX dated on 2015-03-10: Mizuho Securities Downgrades AcelRx Pharmaceuticals to Neutral, Lowers PT to \$5.59

Financial news for ACRX dated on 2015-03-09: AcelRx Pharma Meets Expectations, But Says It Won't Submit New Zalviso Application

Financial news for ACRX dated on 2015-03-09: AcelRx Pharma Reports Q4 EPS -\$0.32 Vs Est -\$0.30, Sales \$226K Vs Est \$590.0K

Financial news for ACRX dated on 2015-03-09: Mizuho Securities Downgrades AcelRx Pharmaceuticals to Neutral

Financial news for ACRX dated on 2015-03-09: Morning Market Losers

Financial news for ACRX dated on 2015-03-09: Benzinga's Top #PreMarket Losers

Financial news for ACRX dated on 2015-03-09: AcelRx Receives FDA Update Regarding NDA Application For Zalviso

Financial news for ACRX dated on 2015-02-26: Mizuho Securities Upgrades AcelRx Pharmaceuticals to Buy, Raises PT to \$14.00

Financial news for ACRX dated on 2014-12-16: AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO

Financial news for ACRX dated on 2014-12-02: AcelRx Reports Receiving of CE Mark Approval for Zalviso

Financial news for ACRX dated on 2014-11-11: Mid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike Higher

Financial news for ACRX dated on 2014-11-11: Mid-Morning Market Update: Markets Edge Lower; D.R. Horton Posts Downbeat Profit

Financial news for ACRX dated on 2014-11-11: Shares of AcelRx Pharmaceuticals Rise 16%; May be Attributed to Positive Guggenheim Note

Financial news for ACRX dated on 2014-11-10: AcelRx Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.13) vs \$(0.22) Est

Financial news for ACRX dated on 2014-11-10: AcelRx Pharmaceuticals Receives International Standards Organization Certification Of Its Quality Management System

Financial news for ACRX dated on 2014-11-06: Mizuho Securities Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to \$6.00

Financial news for ACRX dated on 2014-11-05: Acelrx Pharmaceuticals Announces CEO Richard King To Leave Company

Financial news for ACRX dated on 2014-10-27: AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting

Financial news for ACRX dated on 2014-10-16: AcelRx Pharmaceuticals Announces Update on Patent Portfolio for Zalviso

Financial news for ACRX dated on 2014-09-26: Nike Jumps On Strong Results; Powell Industries Shares Slide

Financial news for ACRX dated on 2014-09-26: Roth Capital Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to \$6.00

Financial news for ACRX dated on 2014-09-26: Stocks Hitting 52-Week Lows

Financial news for ACRX dated on 2014-09-26: Morning Market Losers

Financial news for ACRX dated on 2014-09-26: BlackBerry Ltd, AcelRx & Benzinga's Top PreMarket Losers

Financial news for ACRX dated on 2014-09-26: AcelRx Pharma Offers Regulatory Update for Zalviso: Aiming for NDA Resubmission During Q1'15, But Could Be Later

Financial news for ACRX dated on 2014-08-11: AcelRx Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.30) Which May Not Compare \$(0.26) Est; Revenue of \$71.0K Which May Not

Compare \$40.0K Est

Financial news for ACRX dated on 2014-07-29: Piper Jaffray Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to \$8.00

Financial news for ACRX dated on 2014-07-28: Morning Market Losers

Financial news for ACRX dated on 2014-07-28: AcelRX Selling Off Sharply On FDA Reexamination

Financial news for ACRX dated on 2014-07-28: Benzinga's Top Downgrades

Financial news for ACRX dated on 2014-07-28: Benzinga's Top #PreMarket Losers

Financial news for ACRX dated on 2014-07-28: Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold

Financial news for ACRX dated on 2014-07-28: AcelRx Pharmaceuticals Resume Trading, Now Down 30% Premarket, Following Receipt of CRL from FDA for NDA for Zalviso

Financial news for ACRX dated on 2014-07-28: PREVIEW: AcelRx Pharmaceuticals to Resume Trading at 7:00AM ET

Financial news for ACRX dated on 2014-07-28: Canaccord Genuity Downgrades AcelRx Pharmaceuticals, Inc. to Hold, Lowers PT to \$8.00

Financial news for ACRX dated on 2014-07-25: AcelRx Pharmaceuticals Receives CRL from FDA for NDA for Zalviso

Financial news for ACRX dated on 2014-07-25: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2014-07-25: AcelRx Pharmaceuticals Confirms PDUFA Date for Zalviso is July 27, 2014

Financial news for ACRX dated on 2014-07-07: US Stock Futures Down In Pre-Market Trade

Financial news for ACRX dated on 2014-07-07: Grunenthal Submits European Marketing Authorization Application for ZALVISO, Triggers \$5M Milestone Payment to AcelRx

Financial news for ACRX dated on 2014-06-02: Corporate Events for the Week of Jun. 2nd, 2014

Financial news for ACRX dated on 2014-06-02: AcelRX Announces Chief Commercial Officer To Step Down

Financial news for ACRX dated on 2014-05-19: Filing from Acelrx Pharma Shows Mixed Shelf for Up to \$150M

Financial news for ACRX dated on 2014-05-08: AcelRx Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.22) vs \$(0.23) Est

Financial news for ACRX dated on 2014-04-17: Canaccord Genuity Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy

Financial news for ACRX dated on 2014-04-14: Roth Capital Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces \$22.00 PT

Financial news for ACRX dated on 2014-03-03: AcelRx Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.18) vs \$(0.17) Est

Financial news for ACRX dated on 2014-01-06: RBC Capital Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Outperform, Announces \$15.00 PT

Financial news for ACRX dated on 2013-12-17: McNicoll Lewis Vlak Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to \$16.50

Financial news for ACRX dated on 2013-12-16: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2013-12-16: AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO

Financial news for ACRX dated on 2013-12-13: Benzinga's Top #PreMarket Gainers

Financial news for ACRX dated on 2013-12-13: AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data

Financial news for ACRX dated on 2013-12-02: AcelRx Announces Zalviso NDA Accepted for Filing by FDA

Financial news for ACRX dated on 2013-11-27: Seeking Alpha: 'AcelRx: Huge Potential With Limited Risk'

Financial news for ACRX dated on 2013-11-05: AcelRx Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.26) vs \$(0.19) Est; Revenue of \$548.0K vs \$340.0K Est

Financial news for ACRX dated on 2013-09-30: AcelRx Pharma Issues NDA for Zalviso, Submission Required Payment of \$1.95M to FDA

Financial news for ACRX dated on 2013-08-13: UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals on Numerous Potential Catalysts Ahead

Financial news for ACRX dated on 2013-08-13: Jefferies Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to \$14.00

Financial news for ACRX dated on 2013-08-12: AcelRx Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.22), Inline

Financial news for ACRX dated on 2013-08-09: Form 8-K: Acelrx Pharma, Mallinckrodt Announcing Supply Deal

Financial news for ACRX dated on 2013-07-18: AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock At \$11.65

Financial news for ACRX dated on 2013-07-17: AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Financial news for ACRX dated on 2013-07-02: Benzinga's Volume Movers

Financial news for ACRX dated on 2013-07-02: Hearing Guggenheim Positive on Acelrx

Financial news for ACRX dated on 2013-07-02: AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes

Financial news for ACRX dated on 2013-06-18: UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals Following Model Assumption Updates

Financial news for ACRX dated on 2013-06-18: Jefferies Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to \$13.00

Financial news for ACRX dated on 2013-05-21: Benzinga's Top Pre-Market Gainers

Financial news for ACRX dated on 2013-05-08: AcelRx Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.34) vs \$(0.27) Est; Revenue of \$940.0K vs \$830.0K Est

Financial news for ACRX dated on 2013-05-02: AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting

Financial news for ACRX dated on 2013-04-24: Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial

Financial news for ACRX dated on 2013-04-08: UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01

Financial news for ACRX dated on 2013-04-08: Benzinga's Top Initiations

Financial news for ACRX dated on 2013-04-08: Jefferies Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces \$8.00 PT

Financial news for ACRX dated on 2013-04-08: Jefferies Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces \$8.00 PT

Financial news for ACRX dated on 2013-03-15: Acelrx Pharmceuticals Moves Higher; May be Attributed to Error in Press Release Regarding Available Cash

Financial news for ACRX dated on 2013-02-19: AcelRx Pharma Offers Updates on Clinical Trials

Financial news for ACRX dated on 2013-02-04: McNicoll Lewis Vlak Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces \$13.00 undefined

Financial news for ACRX dated on 2013-01-29: Mizuho Securities Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces \$13.00 PT

Financial news for ACRX dated on 2012-12-18: ACP IV L.P. Files 13D Showing 7.5% Stake in Acelrx Pharma

Financial news for ACRX dated on 2012-12-14: AcetRx Pharma Announces Exercise of Option to Buy Additional Shares

Financial news for ACRX dated on 2012-12-13: Perceptive Advisor Showing 14.25% Stake in AcetRx Pharma

Financial news for ACRX dated on 2012-12-11: AcetRx Spikes Higher

Financial news for ACRX dated on 2012-12-07: Benzinga's Top Pre-Market Gainers

Financial news for ACRX dated on 2012-12-07: AcetRx Pharmaceuticals Prices 12.5M Share Offering at \$3.31/Share

Financial news for ACRX dated on 2012-12-05: A Peek Into The Market Before The Trading Starts

Financial news for ACRX dated on 2012-12-05: AcetRx Pharmaceuticals Announces Proposed 10M Share Secondary Offering

Financial news for ACRX dated on 2012-11-15: FROM EARLIER: AcetRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab(r) PCA System vs. IV PCA Morphine for Post-Operative Pain

Financial news for ACRX dated on 2012-11-14: AcetRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System Meets Primary End-Point

Financial news for ACRX dated on 2012-11-06: AcetRx Pharmaceuticals Reports Q3 EPS \$-0.38 vs \$-0.38 Est; Revenues \$166K vs \$320.00K Est

Financial news for ACRX dated on 2012-11-05: AcetRx Pharmaceuticals Doses the First Subjects in ARX-04 Phase 2 Study

Financial news for ACRX dated on 2012-10-03: AcetRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab PCA System

Financial news for ACRX dated on 2012-08-29: AcetRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

Financial news for ACRX dated on 2012-08-01: AcetRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

Financial news for ACRX dated on 2012-06-20: AcetRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms

Financial news for ACRX dated on 2012-05-30: AcetRx Pharmaceuticals Announces Pricing of a \$10.0M PIPE Financing

Financial news for ACRX dated on 2012-04-12: AcetRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab PCA System, for the Treatment of Acute Post-Operative Pain

Financial news for ACRX dated on 2012-03-08: Benzinga's Microcap Movers for Wednesday March 7, 2012

Financial news for ACRX dated on 2012-03-07: AcetRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab(r) PCA System for the Treatment of Post-Operative Pain

Financial news for ACRX dated on 2012-01-31: AcetRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012

Financial news for ACRX dated on 2011-12-30: Morning Market Losers

Financial news for ACRX dated on 2011-09-28: AcetRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors

Financial news for ACRX dated on 2011-06-30: AcetRx Secures \$20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013

Financial news for ACRX dated on 2011-05-31: AcetRx Announces \$5.6 Million Department of Defense Grant to Develop ARX-04

Financial news for ACRX dated on 2011-05-10: AcetRx European Patent Covering its NanoTab(r) Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period

Financial news for ACRX dated on 2011-04-01: Piper Jaffray Overweight On AcetRx Pharmaceuticals (ACRX)

Financial news for ACRX dated on 2011-03-24: Piper Jaffray Initiates AcelRx
Pharmaceuticals At Overweight, \$7 PT